PT1198490E - Lipopolimeros neutros e composicoes liposomais que contem os mesmos - Google Patents

Lipopolimeros neutros e composicoes liposomais que contem os mesmos

Info

Publication number
PT1198490E
PT1198490E PT00945341T PT00945341T PT1198490E PT 1198490 E PT1198490 E PT 1198490E PT 00945341 T PT00945341 T PT 00945341T PT 00945341 T PT00945341 T PT 00945341T PT 1198490 E PT1198490 E PT 1198490E
Authority
PT
Portugal
Prior art keywords
lipopolymers
liposomes
neutral
alkyl
lipopolimeros
Prior art date
Application number
PT00945341T
Other languages
English (en)
Inventor
Samuel Zalipsky
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT1198490E publication Critical patent/PT1198490E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
PT00945341T 1999-07-14 2000-07-12 Lipopolimeros neutros e composicoes liposomais que contem os mesmos PT1198490E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14381099P 1999-07-14 1999-07-14

Publications (1)

Publication Number Publication Date
PT1198490E true PT1198490E (pt) 2006-06-30

Family

ID=22505748

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00945341T PT1198490E (pt) 1999-07-14 2000-07-12 Lipopolimeros neutros e composicoes liposomais que contem os mesmos

Country Status (24)

Country Link
US (1) US6586001B1 (pt)
EP (1) EP1198490B1 (pt)
JP (1) JP2003505401A (pt)
KR (2) KR20070086708A (pt)
CN (1) CN1193059C (pt)
AT (1) ATE317869T1 (pt)
AU (1) AU769517B2 (pt)
BR (1) BR0012443A (pt)
CA (1) CA2379060A1 (pt)
CY (1) CY1105466T1 (pt)
CZ (1) CZ2002140A3 (pt)
DE (1) DE60026030T2 (pt)
DK (1) DK1198490T3 (pt)
ES (1) ES2255501T3 (pt)
HK (1) HK1048484B (pt)
HU (1) HUP0202177A3 (pt)
IL (2) IL147564A0 (pt)
MX (1) MXPA02000402A (pt)
NO (1) NO20020175D0 (pt)
PL (1) PL352711A1 (pt)
PT (1) PT1198490E (pt)
RU (1) RU2250911C2 (pt)
WO (1) WO2001005873A1 (pt)
ZA (1) ZA200200303B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231697B2 (en) * 2000-12-07 2006-09-07 Enceladus Pharmaceuticals B.V. Composition for treatment of inflammatory disorders
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
AU2003238929A1 (en) 2002-06-07 2003-12-22 Rutgers, The State University Micelle assemblies
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
JP2006519262A (ja) * 2003-02-28 2006-08-24 アルザ・コーポレーシヨン リポソームにより誘導される補体活性化の減少のためのリポソーム組成物
CN100379404C (zh) * 2003-02-28 2008-04-09 阿尔扎公司 用于减少脂质体诱导的补体激活的脂质体组合物
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
BRPI0409424B8 (pt) * 2003-04-15 2021-05-25 Cantab Biopharmaceuticals Patents Ltd composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT2644206T (pt) * 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
JP2007500239A (ja) * 2003-05-30 2007-01-11 アルザ・コーポレーシヨン 薬剤の肺投与の方法
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉rna
WO2005026372A1 (en) 2003-09-15 2005-03-24 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1677765A1 (en) * 2003-10-24 2006-07-12 Alza Corporation Preparation of lipid particles
US20050191344A1 (en) * 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
WO2006051549A2 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
TW200726485A (en) * 2005-07-01 2007-07-16 Alza Corp Liposomal delivery vehicle for hydrophobic drugs
US20070055200A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Needle-free jet injection drug delivery device
WO2008042973A2 (en) * 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
AU2007325631B9 (en) * 2006-11-30 2014-01-30 Nektar Therapeutics Method for preparing a polymer conjugate
US8466255B2 (en) 2007-02-05 2013-06-18 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
WO2008097623A2 (en) 2007-02-07 2008-08-14 Gradalis, Inc. Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
AU2008347250A1 (en) * 2008-01-02 2009-07-16 Tekmira Pharmaceuticals Corporation Screening method for selected amino lipid-containing compositions
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
KR100967833B1 (ko) 2008-05-20 2010-07-05 아이디비켐(주) 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법
US9173840B2 (en) 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5605760B2 (ja) * 2010-01-18 2014-10-15 セイコーエプソン株式会社 吐出用液体、生体試料の吐出方法、及び化合物
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
EP2609106A4 (en) 2010-08-26 2014-03-19 Merck Sharp & Dohme RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI)
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP3202760B1 (en) * 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US8846850B2 (en) 2011-02-22 2014-09-30 Rutgers, The State University Of New Jersey Amphiphilic macromolecules for nucleic acid delivery
US8785660B2 (en) * 2011-03-29 2014-07-22 Nof Corporation Polyoxyalkylene-modified lipid and method for producing the same
US8575380B2 (en) 2011-10-17 2013-11-05 Nof Corporation Branched polyethylene glycol linked with diacyl glycerol, process for producing the same, and polyethylene glycol modified liposome
US9434681B2 (en) 2012-06-15 2016-09-06 Rutgers, The State University Of New Jersey Macromolecules for treating atherosclerosis
US10138203B2 (en) 2014-06-16 2018-11-27 Rutgers, The State University Of New Jersey Antibacterial agents
US9630905B2 (en) 2014-09-08 2017-04-25 Rutgers, The State University Of New Jersey Amphiphilic macromolecules and methods of use thereof
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
SG11201901013WA (en) 2016-08-05 2019-03-28 Rutgers The State University Of New Jersey Thermocleavable friction modifiers and methods thereof
EP4251170A1 (en) 2020-11-25 2023-10-04 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
GB202111757D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
WO2023069987A1 (en) 2021-10-20 2023-04-27 University Of Rochester Rejuvenation treatment of age-related white matter loss cross reference to related application
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741518A (en) 1992-08-03 1998-04-21 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
FR2694893A1 (fr) * 1992-08-03 1994-02-25 Oreal Composition formée d'une dispersion aqueuse de vésicules de lipides amphiphiles non-ioniques stabilisées.
US5786387A (en) * 1994-03-23 1998-07-28 Meiji Seika Kabushiki Kaisha Lipid double-chain derivative containing polyoxyethylene
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
ATE318143T1 (de) * 1996-10-25 2006-03-15 Gilead Sciences Inc Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe

Also Published As

Publication number Publication date
RU2250911C2 (ru) 2005-04-27
DK1198490T3 (da) 2006-06-19
AU769517B2 (en) 2004-01-29
KR100758158B1 (ko) 2007-09-12
MXPA02000402A (es) 2002-07-30
BR0012443A (pt) 2002-04-02
EP1198490B1 (en) 2006-02-15
CY1105466T1 (el) 2010-04-28
ATE317869T1 (de) 2006-03-15
WO2001005873A1 (en) 2001-01-25
KR20020012008A (ko) 2002-02-09
DE60026030T2 (de) 2006-08-10
CN1360611A (zh) 2002-07-24
US6586001B1 (en) 2003-07-01
HUP0202177A3 (en) 2004-05-28
IL147564A0 (en) 2002-08-14
PL352711A1 (en) 2003-09-08
KR20070086708A (ko) 2007-08-27
CA2379060A1 (en) 2001-01-25
JP2003505401A (ja) 2003-02-12
CN1193059C (zh) 2005-03-16
CZ2002140A3 (cs) 2002-05-15
HUP0202177A2 (hu) 2002-12-28
ES2255501T3 (es) 2006-07-01
IL147564A (en) 2007-03-08
DE60026030D1 (de) 2006-04-20
EP1198490A1 (en) 2002-04-24
NO20020175L (no) 2002-01-14
NO20020175D0 (no) 2002-01-14
HK1048484B (zh) 2005-10-14
AU5930300A (en) 2001-02-05
HK1048484A1 (en) 2003-04-04
ZA200200303B (en) 2003-03-26

Similar Documents

Publication Publication Date Title
PT1198490E (pt) Lipopolimeros neutros e composicoes liposomais que contem os mesmos
BR0016040A (pt) Composição, e, processos para aplicação de composição cosmética sobre a pele humana e para aplicação de formulação cosmética transparente sobre a pele humana
MY100947A (en) External pharmaceutical composition.
ATE268158T1 (de) Photostabile sonnenschutzmittel
PE44895A1 (es) Compuesto derivado de benzotiofeno que puede inhibir la perdida osea y disminuir el colesterol en suero
TR200100768T2 (tr) Cetp önleyicileri olarak 4-karboksiamino-2-ikame edilmiş-1,2,3,4- tetrahidrokinolinler
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
WO2000021549A8 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
TR200000560T2 (tr) Dermatolojik kompozisyonlar.
ES2187025T3 (es) Nuevos agentes quelantes de hierro (iii) activos via oral.
SE8404930D0 (sv) Aqueous compositions containing stabilized enzymes
TR199801229T2 (xx) ''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
PT90865A (pt) Processo para a preparacao de compostos de imidazoquinoxalina e de composicoes farmaceuticas que os contem
GB2324528B (en) Cytostatic hydroxamic acid derivatives
Imanaka et al. Esterastin: a potent inhibitor of lysosomal acid lipase
CA2098842A1 (en) Use of host cell phospholipids for inhibiting microbial colonization
ES8203363A1 (es) Un procedimiento para la preparacion de 1-oxo-1h-tiazolo-( 3-2-a) pirimidina.
BR9910677A (pt) Processo de preparação de ésteres de<244>-fenilalanina substancialmenteenantiomericamente puros e utilização de umaenzima total ou parcialmente purificada de tipoprotease
IE801686L (en) 1,3,4-thiadiazines
ES8800165A1 (es) Un procedimiento para preparar derivados de 5-oxo-1-imidazolidinacetamida
IL74150A0 (en) Oximinophosphoric acid derivatives,their preparation and their use as pesticides
ES2187656T3 (es) Derivados de acido fosfinico con actividad inhibidora de metalopeptidasa.
BG51093A1 (en) P-acylanylide of -aminoacids